Glucotrack, Inc. has taken a significant step by entering into a Waiver Agreement with certain holders of warrants. This agreement allows the company to issue new warrants, which could provide it with additional financial flexibility. The move is crucial as it comes at a time when the company is navigating its capital structure and looking to enhance its financial position.

On October 13, 2026, Glucotrack entered into the Waiver Agreement with holders of existing warrants issued under a previous Securities Purchase Agreement. This agreement permits Glucotrack to waive certain restrictions on issuing shares of its common stock. Specifically, the Waiver allows the company to bypass a 90-day restriction on share issuance following the effectiveness of a registration statement.

Glucotrack, Inc. operates in the surgical and medical instruments and apparatus sector. The company is listed under the ticker symbol GCTK on the Nasdaq exchange. As a smaller reporting company, it has been actively managing its financial agreements to adapt to changing market conditions.

The filing states, "The Waiver provides for the waiver and termination of the restriction under Section 5.10(a) of the Purchase Agreement on the Company’s issuance of... shares of Common Stock or Common Stock equivalents." This change is expected to enhance the company's ability to raise capital by issuing new shares.

In exchange for this waiver, Glucotrack has committed to issuing new warrants to purchase an aggregate of 406,198 shares of common stock at an exercise price of $7.50 per share. These new warrants will expire five years from their issuance date and will not be exercisable until the company receives stockholder approval.

The impact of this agreement could be significant for both Glucotrack and its stakeholders. By allowing the issuance of new warrants, the company may improve its financial standing and provide current shareholders with potential upside through the new warrants. This could also affect the broader surgical and medical instruments industry, as companies may look to similar strategies to manage their capital structures.

As for what’s next, the filing does not specify any immediate actions following this agreement. However, the company will likely seek stockholder approval for the issuance of the new warrants as stipulated in the agreement.